Homocysteine is an amino acid produced during normal metabolism and cleared with the help of B vitamins. Elevated levels are associated with vascular inflammation and, most strikingly, with dementia risk: a dose-response meta-analysis links every 5 micromol/L increase with a relative risk of 1.15 for Alzheimer-type dementia. Trials lowering it with B vitamins haven’t improved cognitive outcomes, and that gap is the most important thing to understand about this marker.
- Every 5 micromol/L increase is associated with a relative risk of 1.15 (95% CI 1.04–1.26) for Alzheimer-type dementia.
- A meta-analysis of 11 trials in 22,000 people found B-vitamin lowering produced no significant cognitive benefit.
- B12, B6 and folate are the direct levers for the number itself.
- It feeds the Cognitive Decline and Dementia risk category alongside the Trail Making Test.
Where B vitamins did show an effect
One trial found an effect, in a group selected for being at high risk. 271 people over 70 with mild cognitive impairment were randomised to high-dose folic acid, B12 and B6 or placebo for 24 months.
Mean whole-brain atrophy ran at 0.76 percent per year in the treatment group against 1.08 percent in placebo (P = 0.001). In participants with baseline homocysteine above 13 micromol/L, the atrophy rate was 53 percent lower in the treatment group (P = 0.001).
The honest synthesis: B vitamins reliably lower homocysteine; in unselected populations that has not translated into cognitive benefit; in a high-risk subgroup with elevated baseline homocysteine there is trial evidence of an effect on brain atrophy, which is an imaging endpoint rather than a clinical one.
What homocysteine is and how the body clears it
Homocysteine is an amino acid produced when the body metabolises methionine, which comes from dietary protein. Under normal conditions it is quickly converted onward into other compounds, and that conversion depends on B12, B6 and folate.
When those vitamins are short, or when kidney function is impaired, or when certain genetic variants slow the processing, homocysteine accumulates. Elevated levels are associated with damage to the vascular endothelium, which is the plausible route to both cardiovascular and cognitive risk.
The homocysteine and dementia association
A dose-response meta-analysis of prospective cohort studies found each 5 micromol/L increase in homocysteine associated with a pooled relative risk of 1.15 (95% CI 1.04–1.26) for Alzheimer-type dementia, across five studies. Roughly a 15 percent increase.
The association is specific to Alzheimer-type dementia. The same analysis found no appreciable association with all-cause dementia or with vascular dementia, which its authors attribute to publication bias and low statistical power.
The relationship with Alzheimer-type dementia is linear across the dose range.
On the strength of that association alone, it is a reasonable marker to know.
The gap between the marker and the intervention
Here is where it becomes genuinely interesting, and where most coverage of this marker stops short.. Allocation to B vitamins lowered homocysteine by 26 percent and produced a z-score difference of −0.01 (95% CI −0.03 to 0.02) on global cognitive function, with no significant effect on any individual cognitive domain assessed
If elevated homocysteine causes cognitive decline, lowering it should reduce that decline. That hypothesis has been tested directly. A meta-analysis of 11 randomised trials covering roughly 22,000 people found that B-vitamin supplementation reliably lowered homocysteine, and produced no significant effect on cognitive outcomes.
The supplements worked on the number. The number moving didn’t deliver the benefit its association predicted.
Several explanations remain live. The trials may have intervened too late, after vascular damage had accumulated. Homocysteine may be a marker of some underlying process, poor kidney function, systemic inflammation, general nutritional status, rather than a cause of harm itself. Or a real effect may exist in subgroups these trials couldn’t isolate.
What can’t honestly be claimed is that lowering homocysteine is a demonstrated route to reducing dementia risk. It is a strong risk signal whose modifiability is unproven, and those are different things.
How to read your own homocysteine result
Standard laboratory ranges typically extend to about 15 micromol/L, with optimized targets generally below 10. The association with risk is continuous, so treat it as a gradient rather than a pass-fail line.
An elevated result is worth acting on for reasons that stand independently of the dementia question. It may indicate a B12 or folate deficiency, which carries its own consequences including irreversible neurological damage if prolonged. It may reflect reduced kidney function worth investigating, which is where cystatin C becomes relevant. Both are useful findings.
Homocysteine interpreter
Enter your result to see the band. Worth reading alongside the gap between the marker and the intervention.
What lowers homocysteine
- Adequate B12, B6 and folate. The direct lever on the number. Correcting a genuine deficiency is worthwhile on its own terms; supplementing beyond repletion to chase a lower number is the part the trials tested and didn’t support.
- Reducing alcohol. Heavy intake interferes with folate metabolism and raises levels.
- Not smoking. Smoking is associated with higher homocysteine, among a long list of other reasons.
- Kidney function. Clearance depends on it, so an elevated result alongside other signs of reduced kidney function points upstream rather than at diet.
Note what is missing from this list compared with most markers here: no training lever, and no meaningful body composition lever. This is primarily a nutritional and renal marker.
Where homocysteine belongs in a plan
Homocysteine sits in Systemic Health and feeds the Cognitive Decline and Dementia risk category, alongside the Trail Making Test as a functional counterpart to a blood marker.
Its place in a plan is as information rather than as a target. The strongest evidence-based levers on dementia risk are the ones in the Lancet Commission list: hearing, blood pressure, LDL, activity, smoking, social connection. Homocysteine tells you something real about your risk profile. It isn’t, on current evidence, where the effort belongs.
Sources
Key references for the claims on this page. Where a figure is attributed to a specific study or body, it is named here.
- Dose-response meta-analysis of prospective cohort studies of homocysteine and dementia. Pooled relative risk 1.15 (95% CI 1.04–1.26) for Alzheimer-type dementia per 5 micromol/L increase, from five studies, with no appreciable association for all-cause or vascular dementia.
- Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with 22,000 participants. American Journal of Clinical Nutrition, 2014. No significant effect on cognitive outcomes.
- Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annual Review of Nutrition, 2016. Review of the mechanism and the trial evidence, including the argument that trial populations and timing may explain the null results.
- Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE, 2010. PMC2935890
Frequently asked
What is a normal homocysteine level?
Standard laboratory ranges typically run to about 15 micromol/L, but the association with risk is continuous rather than threshold-based, and optimized targets generally sit below 10. Because the relationship is graded, a result of 14 isn’t equivalent to a result of 8 even though both fall inside the reference range.
If lowering it doesn’t help, why measure it?
Because it is informative even where it isn’t directly actionable. An elevated level can indicate B12 or folate deficiency worth correcting in its own right, and it flags elevated vascular risk that makes the modifiable factors more worth pursuing. What it doesn’t support is treating the number itself as the target.
Why did the B-vitamin trials fail?
Several explanations are plausible and none is settled. The intervention may have come too late, once vascular damage was established. Homocysteine may be a marker of an underlying process rather than a cause of it. Or the effect may be real but confined to subgroups the trials weren’t designed to detect.
Should I take B vitamins to lower it?
If you are deficient in B12 or folate, correcting that is worthwhile regardless of homocysteine. If you are replete, supplementing to push the number down hasn’t been shown to improve cognitive outcomes, and that is what the trial evidence directly tested.
What raises homocysteine?
B12, B6 or folate deficiency, impaired kidney function, some medications including metformin and proton pump inhibitors, smoking, heavy alcohol use, and the common MTHFR genetic variants that reduce folate processing efficiency.
Does the MTHFR gene variant matter?
It is common and modestly raises homocysteine. Commercial testing tends to overstate its significance: the effect on levels is small in most carriers, and carrying the variant doesn’t by itself indicate a problem requiring treatment.
Is homocysteine linked to heart disease too?
It is associated with cardiovascular risk in observational data, and the same pattern applies: trials lowering it with B vitamins didn’t reduce cardiovascular events. The parallel across two disease areas is part of why the causal interpretation is doubted.
How often should I test it?
Annually is more than enough unless you are correcting a diagnosed deficiency, in which case follow the retesting interval your doctor sets. It moves slowly and there is little to gain from frequent measurement.